艾叶油对肺动脉高压大鼠的干预研究

doi:10.5246/jcps.2018.03.019

中国药学(英文版) ›› 2018, Vol. 27 ›› Issue (3): 183-192.DOI: 10.5246/jcps.2018.03.019

艾叶油对肺动脉高压大鼠的干预研究

应茵^1,2, 孙云峰¹, 李宏春¹, 羊波¹, 王晖¹, 吴青梅¹, 黄萍^3*

1. 浙江省立同德医院, 浙江杭州 310012
2. 浙江省中医药研究院, 浙江杭州 310007
3. 浙江省肿瘤医院, 浙江杭州 310022

收稿日期:2017-11-16 修回日期:2018-01-17 出版日期:2018-03-31 发布日期:2018-02-10
通讯作者: Tel.: +86-13858024909, E-mail: hangzhou_hp@163.com
基金资助:
The Natural Science Foundation of Zhejiang Province of China (Grant No. LQ14H280003), the TCM Project of Zhejiang Province (Grant No. 2011ZA006), and the Chinese Integrative Medicine Foundation of Zhejiang Province (Grant No. 2013LYSX020), Zhejiang Provincial Program for the Cultivation of High-level Innovative Heath Talents (Ping Huang), Zhejiang 151 Elites Project, the second level (Ping Huang).

Effects and mechanisms of Artemisia argyi essential oil on monocrotaline-induced pulmonary hypertension in rats

Yin Ying^1,2, Yunfeng Sun¹, Hongchun Li¹, Bo Yang¹, Hui Wang¹, Qingmei Wu¹, Ping Huang^3*

1. Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China
2. Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang 310007, China
3. Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China

Received:2017-11-16 Revised:2018-01-17 Online:2018-03-31 Published:2018-02-10
Contact: Tel.: +86-13858024909, E-mail: hangzhou_hp@163.com
Supported by:
The Natural Science Foundation of Zhejiang Province of China (Grant No. LQ14H280003), the TCM Project of Zhejiang Province (Grant No. 2011ZA006), and the Chinese Integrative Medicine Foundation of Zhejiang Province (Grant No. 2013LYSX020), Zhejiang Provincial Program for the Cultivation of High-level Innovative Heath Talents (Ping Huang), Zhejiang 151 Elites Project, the second level (Ping Huang).

摘要/Abstract

摘要：

本研究建立野百合碱(MCT)诱导的肺动脉高压大鼠动物模型, 观察艾叶油对大鼠肺动脉高压的治疗作用。将80只SD大鼠随机分为正对照组、模型组、波生坦组(0.1 g/kg)和艾叶油组(0.1 g/kg)。造模给药30天后, 测定血流动力学参数、肺指数(LI)和右心肥厚指数(RVHI)。肺组织切片进行苏木素-伊红(HE)染色, 光镜下观察肺组织形态学改变。采用免疫组化法观察大鼠肺组织相关蛋白表达的变化。结果显示, 模型组大鼠肺动脉管壁明显增厚, 管腔明显狭窄, 管周有炎性细胞明显浸润, 且模型组大鼠右心肥厚指数(RVHI)及平均肺动脉压(mPAP)较正常对照组明显升高。艾叶油对肺动脉高压大鼠平均肺动脉压、平均右心室压、右心肥厚指数、肺指数和肺动脉的重构均有不同程度的改善; 大鼠的左心室加心室间隔重量(LV+S)显著降低。在机制研究中, 行野百合碱注射后, NF-κB p65、α-SMA的表达增加, 在相同时间段内模型组和药物治疗组差异有统计学意义, 表明艾叶油可以显著抑制两者的表达。研究表明艾叶油通过下调肺组织NF-κB p65、α-SMA的表达, 抑制肺血管的病变、缓解肺组织损伤、发挥抗肺动脉高压作用。

关键词: 艾叶油, 肺动脉高压, NF-κB, α-SMA

Abstract:

In the present study, we aimed to investigate the effects of Artemisia argyi essential oil (AO) on pulmonary hypertension (PH)inducedbymonocrotaline(MCT)andtoexploretheunderlying mechanism.A total of 80 Sprague-Dawley ratswererandomlydividedintofourgroups as follows:controlgroup, modelgroup,bosentan(0.1g/kg)groupandAO(0.1g/kg)group.After30dofexperiment, hemodynamicparameters,lungandrightventricle hypertrophy indexweredetermined. HEand Immunohistochemistrystainingoflungs were performedto detectthe injuriesandprotein expressions. Theresultsshowedthatlevels of mPAP,mRVP,maxRVP,wW,LI,RV and RVHI as well asthe expressionsofNF-κBp65andα-SMA were increased,smallpulmonaryarterythickened, the cavity of the arteriole narrowed, and there was marked infiltration of inflammatory cells in lungs of rats receiving MCT compared with the normal group. After the administration of AO, the levels of mPAP and mRVP were significantly decreased,and the wW, LI, LV+S and pulmonary arterial remodeling were markedly improved. The expression levels of NF-κB p65 and α-SMAwerereduced by AOcomparedwiththe modelgroup.Ourresultssuggestedthat AOreduced the progressionof PH induced byMCTthroughinhibiting the expressions of NF-κB p65 and α-SMA.

Key words: Artemisia argyi essential oil, Pulmonary hypertension, NF-κB, α-SMA

中图分类号:

R962

Supporting:

应茵, 孙云峰, 李宏春, 羊波, 王晖, 吴青梅, 黄萍. 艾叶油对肺动脉高压大鼠的干预研究[J]. 中国药学(英文版), 2018, 27(3): 183-192.

Yin Ying, Yunfeng Sun, Hongchun Li, Bo Yang, Hui Wang, Qingmei Wu, Ping Huang. Effects and mechanisms of Artemisia argyi essential oil on monocrotaline-induced pulmonary hypertension in rats[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(3): 183-192.

参考文献

[1] Ali, A.; Sheylan, P.; Jessica, C. Pulmonary arterial hypertension and associated conditions. Dis. Mon. 2016, 62, 382-405.

[2] Hoeper, M.; Humbert, M.; Souza, R. A global view of pulmonary hypertension. Lancet Respiratory Medicine. 2016, 4, 22.

[3] Anton, V..; Joanne, A..; Harm, J.B. Pulmonary hypertension. Eur. Respir. Rev. 2016, 25, 4-11.

[4] Yuebin, G.; Zhigang, W.; Ying, X. Anti-inflammatory and blood stasis activities of essential oil extracted from Artemisia argyi leaf in animals. J. Nat. Med. 2016, 70, 1-8.

[5] Monge, C.; León-Velarde, F. Physiological adaptation to high altitude: Oxygen transport in mamals and birds. Physiol. Rev. 1991,71, 1135-1172.

[6] Julian, R.J.; Caston, L.J.; Leeson, S. The effect of dietary sodium on right ventricular failure-induced ascites, gain and fat deposition in meat-type chickens. Canadian J. Vet. Res. 1992, 56, 214-219.

[7] Wei, B.; Du, J.; Qi, J. L-arginine impacts pulmonary vascular structure in rats with an aortocaval shunt. J. Surg. Res. 2002, 108, 20-31.

[8] Voelkel, N.F.; Cool, C.; Lee S.D.; Wright, L.; Geraci, M.W.; Tuder, R.M. Primary pulmonary hypertension between inflammation and cancer. Chest. 1998, 114, 225-230.

[9] Iwasaki, T.; Takahashi, T.; Shimizu, H. Increased pulmonary heme oxygenase-1 and delta-aminolevulinate synthase expression in monocrotaline induced pulmonary hypertension. Curr. Neurovascular Res. 2005, 2, 133-139.

[10] Enomoto, A.; Kimura, H.; Chairoungdua, A. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002, 417, 447-452.

[11] Kevin, B.M.; James, R.K.; Sharon, I.S.R. Pulmonary arterial hypertension: new insights and new hope. Respirology. 2006, 11, 6-17.

[12] Ralph, T.S.; Hossein, A.G.; Martin, R.W. Mechanisms of disease: pulmonary arterial hypertension. Nature Rev. Cardiology. 2011, 8, 443-455.

[13] Zaiman, A.; Fijalkowska, I.; Hassoun, P.M. One Hundred Years of Research in the Pathogenesis of Pulmonary Hypertension. Am. J. Respir. Cell Mol. Biol. 2005, 33, 425-431.

[14] St.fano, A.D.; Caramori, G.; Oates, T. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 2002, 20, 556-563.

[15] Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986, 46, 705-716.

[16] Blackwell, T.S.; Christman, J.W. The role of nuclear factor-kappa B in cytokine gene regulation. Am. J. Respir. Cell & Mol. Biol. 1997, 17, 3-9.

[17] Christman, J.W.; Sadikot, R.T.; Blackwell, T.S. The role of nuclear factor-kappa B in pulmonary diseases. Chest. 2000, 1482-1487.

[18] Wright, J.G.; Christman, J.W. The Role of Nuclear Factor Kappa B in the Pathogenesis of Pulmonary Diseases: Implications for Therapy. Treat. Respir. Med. 2003, 211-219.

[19] Muraoka, K.; Shimizu, K.; Sun, X. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation. 1997, 63, 466-470.

[20] Ao, Q.; Xiong, M.; Hao, C. Changes of NF-κB and P53 during Hypoxic Pulmonary Arterial Smooth Muscle Cell Proliferation and Apoptosis. Acta Univ. Med. Tongji. 2002.

[21] Jiménez-Garza, O.; Camacho, J.; Ibarra, A. Early Effects of Modulating Nuclear Factor-κB Activation on Traumatic Spinal Cord Injury in Rats. Ann. NY Acad. Sci. 2005, 1053, 148-150.

[22] Mamoru, O.; Masanori, T.; Masato, S. The role of nuclear factor-kappa B in the regulation of endothelin-1 production by nitric oxide. European J. Pharmacol. 2003, 472, 159-164.
[23] Mandy, W.; Elizabeth, G.W.; Sonya C.B. Role for Nuclear Factor-κB and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells. Mol. Pharmacol. 2003, 64, 923-931.

艾叶油对肺动脉高压大鼠的干预研究

Effects and mechanisms of Artemisia argyi essential oil on monocrotaline-induced pulmonary hypertension in rats

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	洪倩, 王增慧, 杨阳, 高璐, 闫兆. 银杏二萜内酯葡胺注射液通过调控炎症和凋亡信号通路减轻OGD/R诱导的细胞损伤[J]. 中国药学(英文版), 2020, 29(7): 455-469.
[2]	蒋雯, 孙超, 王珏, 辛倩, 李开霖, 亓同钢, 栾云. 黄芩苷通过抑制血管重构对实验性肺动脉高压的治疗作用研究[J]. 中国药学(英文版), 2020, 29(10): 719-728.
[3]	张烨, 郑丹萍, 水梦洋, 刘晔, 刘晓岩, 王银叶. 新化合物W026B通过抑制炎性细胞因子的产生减轻缺血性脑损伤, 与tPA合用作用增强[J]. 中国药学(英文版), 2018, 27(10): 675-685.
[4]	陈溢欣, 袁霞, 葛泽梅, 冉福香, 吴军, 李润涛, 崔景荣. 新型蛋白酶体抑制剂YSY-01A对人胃癌MGC-803的作用及相关蛋白研究[J]. 中国药学(英文版), 2014, 23(9): 601-609.
[5]	马婉婉, 唐叔南, 曹明楠, 葛泽梅, 李润涛, 余四旺. 氨基二硫代甲酸酯类化合物IC5抑制结直肠癌细胞增殖及干预炎症性肠病相关结直肠癌发展[J]. 中国药学(英文版), 2014, 23(9): 610-616.